Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antigen Processing Pathways

Antigen Processing Pathways

MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...

The Equilibrium Binding Constant and Binding Strength

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:

Antigens Involved in Adaptive Immunity

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Therapeutic bacteria-trained NK cells confer long-term protection against cancer metastasis.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Same author

A single polypeptide vaccine derived from multiple antigens confers protection against staphylococcus aureus infection in mice.

Tropical diseases, travel medicine and vaccines·2026

Same author

Discovery of novel, high-affinity HBV T-cell epitopes by molecular dynamics-augmented proteome-wide screening.

Protein science : a publication of the Protein Society·2026

Same author

Identifying Structural Factors Governing the Photodynamic Activity of Phthalocyanines.

Journal of medicinal chemistry·2026

Same author

Engineering M13 Filamentous Phages to Target Dendritic Cells and Elicit Anti-Tumour Immunity.

Small (Weinheim an der Bergstrasse, Germany)·2025

Same author

Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1.

Nature communications·2025

Search research articles

Related Experiment Video

Updated: Jul 27, 2025

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

A Bayesian approach to estimate MHC-peptide binding threshold.

Ran Liu¹, Ye-Fan Hu^2,3,4, Jian-Dong Huang^2,5,6,7,8

¹Department of Statistics, The Chinese University of Hong Kong, Hong Kong SAR, China.

Briefings in Bioinformatics

|June 6, 2023

Summary

This summary is machine-generated.

This study introduces a new Bayesian model to automatically determine the Major Histocompatibility Complex (MHC)-peptide binding threshold. This data-driven approach improves accuracy for immunotherapy applications.

Keywords:

Binding threshold MHC-peptide binding Motif sampling

More Related Videos

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

Published on: October 22, 2012

Related Experiment Videos

Last Updated: Jul 27, 2025

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

Published on: October 22, 2012

Area of Science:

Immunology
Computational Biology
Bioinformatics

Background:

Major Histocompatibility Complex (MHC)-peptide binding is crucial for T-cell recognition and immunotherapy.
Existing methods predict binding affinity but struggle to infer accurate binding thresholds, often using arbitrary values.
Different MHC molecules may possess distinct binding thresholds, necessitating a data-driven approach.

Purpose of the Study:

To develop an automated, data-driven method for determining MHC-peptide binding thresholds.
To infer binding sites, binding affinity, and binding thresholds simultaneously.
To provide a posterior distribution for the binding threshold for each MHC.

Main Methods:

Proposed a Bayesian model for joint inference of core locations, binding affinity, and binding threshold.
Conducted simulation studies with varying motif distributions and random sequence proportions.
Applied the model to real-world MHC-peptide binding data.

Main Results:

The Bayesian model accurately estimates binding thresholds, providing a posterior distribution for each MHC.
Simulation studies demonstrated the model's accuracy and robustness across different scenarios.
The model outperformed commonly used arbitrary thresholds when applied to real data.

Conclusions:

The developed Bayesian model offers an accurate and data-driven method for determining MHC-peptide binding thresholds.
This approach enhances the prediction of T-cell antigen presentation for immunotherapy.
The findings suggest a more precise way to analyze MHC-peptide interactions than traditional ad hoc criteria.